With just over a month until the World Vaccine Congress in Barcelona, our start-up zone is continuing to grow! This week we continue introducing organisations that have already secured their spaces in the zone. To see previous introductions head over to our technology section.   

Why be a start-up at the World Vaccine Congress?    

Start-ups whose applications are successful are entitled to several unique benefits, including exhibition wall space, 2 complimentary passes, and marketing materials. For the first time at this event, there is the opportunity to participate in a 5-minute pitch during lunch breaks, an exciting way of introducing yourselves to colleagues and potential partners.     

Our wonderful start-up manager, Isabella Aung, will receive your application and guide you through the process. She is looking forward to hearing more from interested companies, so do get in touch with her here via email (isabella.aung@terrapinn.com) or head straight to the application page here.     

“I am super excited to connect with and welcome even more start-ups to our start-up zone at our Congress this October! It’s going to be our biggest and most exciting start-up zone yet!” 
Piezo Therapeutics
  • Aims to transform the delivery of nucleic acid medicines to enable improved safety, affordability, and scalability.
  • Developing a uniquely engineered platform that uses electric pulses and microneedles to deliver a broad range of therapeutics inside the body. Its piezoelectric technology offers improved safety and efficacy, and is simple, cost-effective, and rapid to produce at scale.
  • Piezo’s platform has the potential to replace lipid nanoparticles for the delivery of RNA/DNA medicines by addressing key issues including high costs, manufacturing complexity, and poor stability.
  • It was founded by experts in the field of drug delivery and commercial translation and is backed by Open Philanthropy. The diverse team aims to help translate the next generation of nucleic acid medicines.
Prime Vector Technologies (PRIME)
  • A clinical stage biotech company from Tübingen, Germany, developing vaccines based on a proprietary Orf virus vector platform technology.
  • They offer licenses for platform technology, as well as customer-specific and fully-owned vaccine products for the prevention and therapy of infectious diseases and cancer.
  • The single vectored vaccines elicit strong cellular and protective humoral immune responses, are safe and well tolerated by humans, and can be designed to express multiple antigens and immunostimulatory molecules simultaneously to orchestrate the immune system to maximise immunity.
  • Due to a lack of neutralising anti-vector immunity, the vaccines can be administered repeatedly without loss of efficacy or need for an adjuvant.
  • The team is developing innovative supply chain services for hospitals and health care centres. They have launched a digital platform for vaccine last mile delivery; this is currently operational in France for hospitals and in Cameroon for the entire vaccine distribution network: Expanded Programme on Immunisation central and regional stocks, Health Districts, and vaccination centres.
  • The digital platform is intended to connect all care centres involved in the vaccination campaigns and provide real time inventory visibility over the distribution network. By monitoring all stock movements, it contributes to a better vaccination effectiveness by drastically reducing wastage and improving vaccine allocation.
  • The platform is web-application accessible from a PC or mobile phone, and a disconnected mode is available for remote areas with limited network access.
  • The deployment of the platform is easy and quick with the onboarding of local health workforce.
Q-Vant Biosciences
  • A privately-held multinational company that stands at the vanguard of innovation in the global human and animal vaccine markets. The company has revolutionised the industry by solving the persistent supply chain problem of QS-21 and other quillaja-based saponin adjuvants, which are integral to several new vaccines.
  • Q-Vant’s groundbreaking solution harnesses a disruptive technology, multiplying the potential for sustainable QS-21 supply by an unprecedented factor of 1,000. The innovation has set a new industry benchmark, enabling an annual production capacity that could exceed 20 billion vaccine doses.
  • Aside from technological prowess, Q-Vant is deeply committed to sustainability. The company’s novel approach not only addresses supply chain constraints but also promotes a sustainable ecosystem, setting a new standard in the industry.
  • With a pioneering role in meeting the vaccine industry’s demands, Q-Vant is not just a game-changer but a life-changer, demonstrating that the fusion of technological innovation and sustainability can deliver extraordinary outcomes.
  • A Finnish biotech company currently developing an intranasal COVID-19 vaccine.
  • The IMP manufacturing has started and they are planning to start the Phase I clinical trial with around 100 subjects at the beginning of 2024.
  • With a good understanding of nasal physiology and the challenges of mucosal vaccine administration, and a highly immunogenic adenovirus vector vaccine platform, they are confident to overcome the traditional intranasal administration hurdles.
  • The same vaccine technology can also enable the rapid development of new vaccines against other viruses in various diseases.


If you would like to join your colleagues in this exciting and continuously growing start-up zone, fill out an application here or contact Isabella here: isabella.aung@terrapinn.com    

Stay tuned for more start-up news, and make sure you subscribe to our weekly newsletters!